Homocysteine Triggers Mucosal Microvascular Activation in Inflammatory Bowel Disease
- 1 April 2005
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 100 (4) , 886-895
Abstract
Increased homocysteine contributes to the pathophysiology of several chronic inflammatory diseases. Whether homocysteine could participate in mucosal inflammation in inflammatory bowel disease (IBD) has not been explored yet. Our aims were to study the levels of plasma and mucosal homocysteine in IBD patients and to assess whether homocysteine can trigger an inflammatory reaction on human intestinal microvascular endothelial cells (HIMECs). Homocysteine was measured in the plasma, mucosal biopsy, and lamina propria mononuclear cell (LPMC) supernatants from normal and IBD subjects. HIMEC were cultured in presence of homocysteine, TNF-α, or folic acid, alone or in combination. Expression of vascular cell adhesion molecule 1 (VCAM-1) and intercellular cell adhesion molecule 1 was measured by flow cytometry and monocyte chemoattractant protein-1 (MCP-1) production by ELISA. Phosphorylation of p38 and p42/44 was assessed by immunoblot in HIMEC extracts. T-cell- and monocyte-HIMEC adhesion assays were used to evaluate the impact of homocysteine on leukocyte adhesion to intestinal endothelial cells. Patients with IBD displayed significantly higher homocysteine plasma and mucosal levels than control subjects. IBD-derived LPMC released higher homocysteine than control-derived LPMC. Treatment of HIMEC with homocysteine, and synergistically with the combination of TNF-α and homocysteine, triggered HIMEC inflammation, resulting in VCAM-1 up-regulation, MCP-1 production, and p38 phosphorylation. These events lead to an increased capacity of HIMEC to adhere T- and monocyte cells and were blocked by folic acid treatment. Homocysteine is increased in both the mucosa and plasma of patients with Crohn's disease and ulcerative colitis and contributes to the inflammatory state of the mucosal IBD endothelium. Therefore, homocysteine could play a proinflammatory role in IBD, which can be efficiently targeted by folic acid supplementation.Keywords
This publication has 41 references indexed in Scilit:
- Moderate Hyperhomocysteinemia and Immune ActivationCurrent Pharmaceutical Biotechnology, 2004
- Hyperhomocysteinemia and its role in the development of atherosclerosisClinical Biochemistry, 2003
- Increased plasma homocysteine levels without signs of vitamin B12 deficiency in patients with multiple sclerosis assessed by blood and cerebrospinal fluid homocysteine and methylmalonic acidMultiple Sclerosis Journal, 2003
- Influence of Hyperhomocysteinemia on the Cellular Redox State – Impact on Homocysteine-Induced Endothelial DysfunctionClinical Chemistry and Laboratory Medicine (CCLM), 2003
- Interactions of Homocysteine, Nitric Oxide, Folate and Radicals in the Progressively Damaged EndotheliumClinical Chemistry and Laboratory Medicine (CCLM), 2003
- Hyperhomocysteinaemia in Behcet's diseaseRheumatology, 2001
- Homocysteine Levels in Patients with StrokeCNS Drugs, 2001
- Abnormal homocysteine metabolism in rheumatoid arthritisArthritis & Rheumatism, 1997
- Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosusThe Lancet, 1996
- Homocysteine and vascular diseaseNature Medicine, 1996